A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $12 to $30
Annexon Biosciences' ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential
Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment
Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Express News | Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)
Annexon Insider Buyers Pleased With US$571k Return On Investment
